Clinical trial · no report yet · Phase 1/Phase 2
ACTengine
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT03686124 ↗
- Recruiting
- Immatics US, Inc.
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Study Evaluating Genetically Modified Autologous T Cells Expressing a TCR Recognizing a Cancer/Germline Antigen as Monotherapy or in Combination With Nivolumab in Patients With Recurrent and/or Refractory Solid Tumors
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Refractory Cancer; Recurrent Cancer; Solid Tumor, Adult; Cancer
- Interventions
- IMA203 Product; IMA203 product- flat dose; IMA203CD8 Product; Nivolumab; IMADetect®
- Arms
- Dose Escalation A (closed to enrollment) · Experimental
- Extension Cohort A · Experimental
- Extension Cohort B (closed to enrollment) · Experimental
- Extension Cohort AA · Experimental
- Uveal Melanoma · Experimental
- Dose Escalation B · Experimental
- Extension Cohort C · Experimental
- Extension Cohort D · Experimental
- Ovarian · Experimental
- Endometrial · Experimental
- Head and Neck, Lung, and Triple Negative Breast Cancer · Experimental
- Rare Cancers · Experimental
- Enrollment
- 375 (estimated)
- Primary outcomes
- Phase 1: Determine the MTD and/or recommended dose for extension for IMA203/IMA203CD8
- Phase 1 and Phase 2: Number and grade of treatment emergent adverse events and adverse events of special interest in subjects treated.
- Phase 1 and Phase 2: Tumor Response
- Sponsor
- Immatics US, Inc.
- Start
- May 14, 2019
- Primary completion
- Dec 2028 (estimated)
- Results posted
- No
- Registry record
- NCT03686124 · updated May 13, 2026
Publications
linked from the registry- Wermke M, Araujo DM, Chatterjee M, Tsimberidou AM, Holderried TAW, Jazaeri AA, Reshef R, Bokemeyer C, Alsdorf W, Wetzko K, Brossart P, Aslan K, Backert L, Bunk S, Fritsche J, Gulde S, Hengler S, Hilf N, Hossain MB, Hukelmann J, Kalra M, Krishna D, Kursunel MA, Maurer D, Mayer-Mokler A, Mendrzyk R, Mohamed A, Pozo K, Satelli A, Letizia M, Schuster H, Schoor O, Wagner C, Rammensee HG, Reinhardt C, Singh-Jasuja H, Walter S, Weinschenk T, Luke JJ, Britten CM. Autologous T cell therapy for PRAME+ advanced solid tumors in HLA-A*02+ patients: a phase 1 trial. Nat Med. 2025 Jul;31(7):2365-2374. doi: 10.1038/s41591-025-03650-6. Epub 2025 Apr 9. PubMed 40205198